PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Esclerose Lateral Amiotrófica Esclerose Lateral Amiotrófica 12 R EFERÊNCIAS BIBLIOGRÁFICAS 1. Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry. 1992;55(12):1106-15. 2. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68(13):1002-7. 3. Phukan J, Hardiman O. The management of amyotrophic lateral sclerosis. J Neurol. 2009;256(2):176-86. 4. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369(9578):2031-41. 5. Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: “prepare for the worst and hope for the best”. JAMA. 2007;298(2):207-16. 6. Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep. 2006;6(1):37-46. 7. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526-8. 8. Hayashi H, Oppenheimer EA. ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications. Neurology. 2003;61(1):135-7. 9. Li TM, Day SJ, Alberman E, Swash M. Differential diagnosis of motoneurone disease from other neurological conditions. Lancet. 1986;2(8509):731-3. 10. Wilbourn AJ. Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. J Neurol Sci. 1998;160(Suppl 1):S25-9. 11. Meininger V. Getting the diagnosis right: beyond El Escorial. J Neurol. 1999;246(Suppl 3):III10-2. 12. Chiò A. ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol. 1999;246(Suppl 3):III1-5. 13. Brooks BR, Miller RG, Awash M, Munsat TL; World Federation of Neurology Research Group on Motor Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-9. 14. Baek WS, Desai NP. ALS: pitfalls in the diagnosis. Pract Neurol. 2007;7(2):74-81. 15. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;(1):CD001447. 16. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2002;(3):CD002064. 17. Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2004;(3):CD004302. 18. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999;52(7):1427-33. 19. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(3):201-6. 20. Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(2):107-17. 21. de Paulis T. ONO-2506. Ono. Curr Opin Investig Drugs. 2003;4(7):863-7. 22. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004;62(10):1845-7. 23. Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci. 2005;26(4):285-7. 24. Ryberg H, Askmark H, Persson LI. Adouble-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand. 2003;108(1):1-8. 25. Gordon PH, Doorish C, Montes J, Mosley RL, Diamond B, Macarthur RB, et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology. 2006;66(7):1117-9. 26. Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs. 2006;7(1):70-80. 281